中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2013年
11期
40-42
,共3页
晚期胃癌%替吉奥胶囊%多西他赛%FOLFOX4
晚期胃癌%替吉奧膠囊%多西他賽%FOLFOX4
만기위암%체길오효낭%다서타새%FOLFOX4
Advanced gastric carcinoma%S-l%Docetaxel%FOLFOX4
目的 比较替吉奥胶囊(S-1)联合多西他赛与FOLFOX4方案治疗晚期胃癌的临床疗效及安全性.方法 将75例初治和复治的晚期胃癌患者随机分为实验组和对照组.实验组37例,应用替吉奥胶囊80 mg/m2,口服,早晚餐后各1次,第1～14天；多西他赛38 mg/m2,第1、8天,静脉滴注1h.21 d为1个化疗周期,至少完成2个周期.对照组38例应用FOLFOX4方案,即:奥沙利铂85 mg/m2静脉注射2h,第1天；亚叶酸钙200 mg/m2静脉滴注,第1、2天；5-氟脲嘧啶(5-Fu)400 mg/m2,静脉推注,第1天；5-Fu 600 mg/m2,持续静脉滴注22 h,第1、2天.14 d为1个周期,至少完成2个周期.评价两组的客观疗效及不良反应.结果 实验组和对照组的有效率分别为56.76％、47.37％,两组比较差异无统计学意义(P＞0.05).实验组和对照组的腹泻及恶心、呕吐的发生率均较对照组低,差异有统计学意义(P均＜ 0.05).其他毒副作用比较差异无统计学意义(P均＞0.05).结论 替吉奥联合多西他赛与FOLFOX方案近期疗效无明显差异,但替吉奥联合多西他赛毒副作用较轻,对年老体弱者可能更适合.
目的 比較替吉奧膠囊(S-1)聯閤多西他賽與FOLFOX4方案治療晚期胃癌的臨床療效及安全性.方法 將75例初治和複治的晚期胃癌患者隨機分為實驗組和對照組.實驗組37例,應用替吉奧膠囊80 mg/m2,口服,早晚餐後各1次,第1～14天；多西他賽38 mg/m2,第1、8天,靜脈滴註1h.21 d為1箇化療週期,至少完成2箇週期.對照組38例應用FOLFOX4方案,即:奧沙利鉑85 mg/m2靜脈註射2h,第1天；亞葉痠鈣200 mg/m2靜脈滴註,第1、2天；5-氟脲嘧啶(5-Fu)400 mg/m2,靜脈推註,第1天；5-Fu 600 mg/m2,持續靜脈滴註22 h,第1、2天.14 d為1箇週期,至少完成2箇週期.評價兩組的客觀療效及不良反應.結果 實驗組和對照組的有效率分彆為56.76％、47.37％,兩組比較差異無統計學意義(P＞0.05).實驗組和對照組的腹瀉及噁心、嘔吐的髮生率均較對照組低,差異有統計學意義(P均＜ 0.05).其他毒副作用比較差異無統計學意義(P均＞0.05).結論 替吉奧聯閤多西他賽與FOLFOX方案近期療效無明顯差異,但替吉奧聯閤多西他賽毒副作用較輕,對年老體弱者可能更適閤.
목적 비교체길오효낭(S-1)연합다서타새여FOLFOX4방안치료만기위암적림상료효급안전성.방법 장75례초치화복치적만기위암환자수궤분위실험조화대조조.실험조37례,응용체길오효낭80 mg/m2,구복,조만찬후각1차,제1～14천；다서타새38 mg/m2,제1、8천,정맥적주1h.21 d위1개화료주기,지소완성2개주기.대조조38례응용FOLFOX4방안,즉:오사리박85 mg/m2정맥주사2h,제1천；아협산개200 mg/m2정맥적주,제1、2천；5-불뇨밀정(5-Fu)400 mg/m2,정맥추주,제1천；5-Fu 600 mg/m2,지속정맥적주22 h,제1、2천.14 d위1개주기,지소완성2개주기.평개량조적객관료효급불량반응.결과 실험조화대조조적유효솔분별위56.76％、47.37％,량조비교차이무통계학의의(P＞0.05).실험조화대조조적복사급악심、구토적발생솔균교대조조저,차이유통계학의의(P균＜ 0.05).기타독부작용비교차이무통계학의의(P균＞0.05).결론 체길오연합다서타새여FOLFOX방안근기료효무명현차이,단체길오연합다서타새독부작용교경,대년로체약자가능경괄합.
Objective To compare the curative efficacy and safety of the combination of S-1 and docetaxel and FOLFOX4 in the treatment of patients with advanced gastic carcinoma.Methods Seventy-five patients with advanced gastric carcinoma were randomly divided into two groups.Experimental group(37 cases) were treated with the combination of S-1 capsule and docetaxel,one treatment cycle covered 3 weeks.Control group were treated with FOLFOX4 therapy,14 days as a cycle.The efficacy and toxicity were evaluated after 2 cycles.Results The overall effective rate of experimental group and control group was 56.76％ and 47.37％ respectively.There was no significant difference between the two groups (P ＞ 0.05).The main adverse reactions included myelo-depression,nausea,vomiting and diarrhea.Conclusions Two groups have similar effects in the treatment of advanced gastric carcinoma,and the toxicity of the regiment of S-1 combined with docetaxel is mild and tolerable.
